Aiming to advance the development of medical products for brain and nervous system disorders, the US Food and Drug Administration (FDA) has launched a new agency-wide program, with its first effort focused on preventing Alzheimer’s disease.
The initiative, called the Neuroscience Advancement and Innovation Nexus (NAIN), is designed to support